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Background: Economic growth in low- and middle-income countries (LMIC) has raised interest in how
disease burden patterns are related to economic development. Meanwhile, poverty-related diseases are
considered to be neglected in terms of research and development (R&D).
Objectives: Developing intuitive and meaningful metrics to measure how different diseases are related to
poverty and neglected in the current R&D system.
Design: We measured how diseases are related to economic development with the income relation factor
(IRF), defined by the ratio of disability-adjusted life-years (DALYs) per 100,000 inhabitants in LMIC versus
that in high-income countries. We calculated the IRF for 291 diseases and injuries and 67 risk factors included
in the Global Burden of Disease Study 2010. We measured neglect in R&D with the neglect factor (NF),
defined by the ratio of disease burden in DALYs (as percentage of the total global disease burden) and R&D
expenditure (as percentage of total global health-related R&D expenditure) for 26 diseases.
Results: The disease burden varies considerably with the level of economic development, shown by the IRF
(median: 1.38; interquartile range (IQR): 0.796.3). Comparison of IRFs from 1990 to 2010 highlights general
patterns of the global epidemiological transition. The 26 poverty-related diseases included in our analysis of
neglect in R&D are responsible for 13.8% of the global disease burden, but receive only 1.34% of global health-
related R&D expenditure. Within this group, the NF varies considerably (median: 19; IQR: 652).
Conclusions: The IRF is an intuitive and meaningful metric to highlight shifts in global disease burden
patterns. A large shortfall exists in global R&D spending for poverty-related and neglected diseases, with
strong variations between diseases.
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O
ver the past 20 years, rapid economic change in
low and middle income countries has raised in-
terest in how disease burden patterns are related
to economic development. It is commonly held that in the
course of the global epidemiological transition, a growing
number LMIC face a double burden of both poverty-
related, communicable diseases and affluence-related, non-
communicable diseases at the same time (1, 2).
Meanwhile, poverty-related diseases are still consid-
ered to be neglected in research and development (R&D).
While affluence-related diseases may attract considerable
commercial R&D funding, many poverty-related diseases
are considered neglected in the current R&D system
(310). Differing assessments of the extent and relevance
of this so-called R&D gap influence the broader debate
on global health R&D policy (5, 11, 12). Concerns about
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these issues have led to negotiations on a possible Global
Health R&D Convention, as proposed by the Consulta-
tive Expert Working Group on Research and Develop-
ment (CEWG) commissioned by the World Health
Organization (WHO), subsequent debates on a Global
Health R&D Observatory, and ongoing WHO-sponsored
R&D demonstration projects (5, 6, 1317).
Based on a definition of Type I, II, and III diseases dis-
cussed in a background document prepared by the WHO
Secretariat (18) and by Røttingen et al. (13), we propose
an income relation factor (IRF) as a quantitative, intui-
tive, and meaningful metric for the degree to which dis-
eases, disease groups, and risk factors are related to the
level of economic development. Based on the IRF and
work done by the WHO Secretariat (18) and Røttingen
et al. (13), who used disease burden data for 2004, we pro-
pose quantitative definitions for poverty- and affluence-
related diseases based on data from the Global Burden
of Disease Study 2010 (GBD 2010). Moreover, we assess
the size and the characteristics of the gap in R&D for a
subset of poverty-related diseases by comparing global
R&D expenditure and disease burden.
Methods
We conduct our analysis in two steps. First, we analyze
291 diseases, injuries and cause groups, and 67 risk
factors and risk factor clusters included in the GBD 2010
(19, 20) with regard to their relatedness to the level of
economic development. Second, we analyze the R&D gap
for 26 diseases and disease groups commonly defined as
poverty related and neglected and for which sufficiently
specific R&D expenditure data were available, by com-
paring disease burden and R&D expenditure. An over-
view of our methodology is given in Fig. 1.
Total global disease burden and
total global health-related research and development (R&D) expenditure
Global Burden of Disease Study 2010(GBD 2010): 241 diseases, 51 cause groups and
67 risk factors of death and disability causing 2.490 billion disability-adjusted life years
(DALYs) in 2010 (Murray et al. 2012 and Lim et al. 2012).
Total world-wide health related R&D expenditure: 265.9 billion US$(2008-2012 annual 
average) (Chakma et al. 2014).
Relatedness of diseases to the level of economic development
Measured with the income relation factor (IRF):
(DALYs = disability-adjusted life years, LMIC = low and middle income 
countries, HIC = high income countries)
R&D expenditure and neglect in R&D
Measured with the neglect factor (NF):
Table 2
241 causes of death and disability
16 strongly affluence related (Type Ia)
27 moderately affluence related (TypeIb)
117 unrelatedto the level of economic 
development (Type Ic)
53 moderately poverty related (Type II)
28 strongly poverty related (Type III)
Table 3




from 0.4 to 421.3)
Table 4
26 poverty-related and neglected diseases, Neglect 
Factor ranging from
0.04 to 544
Of these: 26 poverty-related and neglected diseases (PRND)
as defined by G-FINDER,causing 343 million DALYs in 2010
(13.8 % of total) and receiving 3.6 billion US$ R&D expenditure
(2008-2012 annual average, 1.34% of total) (G-FINDER 2014).
4 PRND defined by 
G-FINDER but
not included in 
GBD 2010.
Table 4
26 poverty related and neglected diseases
15 Type III diseases – 8Type II diseases – 3Type Ia diseases
DALYs per 100,000 inhabitants in LMIC
DALYs per 100,000 inhabitants in HIC
Disease burden in DALYs (as % of the
total gobal disease burden)
R D expenditure (as % of total global
health — related R D expenditure)
Fig. 1. Data sources and analytical steps of our analysis of income relatedness and neglect in terms of research & development
(R&D).
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Relatedness of diseases to the level of economic
development
In 2001, the WHO Commission on Macroeconomics and
Health proposed a scheme for classifying diseases accord-
ing to their relatedness to the level of economic develop-
ment which distinguishes three disease types (disease
Types I, II, and III, see Table 1) (18, 21). The WHO
Secretariat (18), as well as Røttingen et al. (13), propose
the following ratio to operationalize this classification
scheme, based on DALY figures (disability-adjusted life
years, a composite figure that captures both premature
mortality and the prevalence and severity of ill-health) for
different world regions:
DALYs per 100; 000 inhabitants in low- and middle-income countries
DALYs per 100; 000 inhabitants in high-income countries
We use the term income relation factor (IRF) for this
ratio. We define Type III diseases (IRF]35) as strongly
poverty related, and Type II diseases (3]IRFB35) as
moderately poverty related. To accommodate all condi-
tions, and not just those related to poverty, we expand the
existing classification by subdividing the group of Type I
diseases (0]IRFB3) into three groups: conditions un-
related to economic development (Type Ic, 0.66]IRFB3),
moderately affluence-related conditions (Type Ib, 0.33]
IRFB0.66), and strongly affluence-related conditions
(Type Ia, IRFB0.33). We then calculate the IRF for
all diseases, injuries and cause groups included in the
GBD 2010 and categorize them according to the above
definitions. An overview of the different disease categories
and their definitions is given in Table 1. Based on DALYs
attributable to the independent effects of risk factors and
risk factor clusters as estimated by the GBD 2010, we
calculate the IRF for the 67 risk factors and risk factor
clusters included in the GBD 2010 (20).
R&D expenditure and neglect in R&D
In the term neglected diseases, the word neglect refers to
the notion that for the diseases in question, the proportion
of current R&D efforts is considered to fall short of the
proportion which would be equitable and efficient under
the given conditions. In our operationalization of neglect,
we use R&D expenditure as a yardstick for current R&D
efforts, as it reflects both the commercial interest of
industry and the political commitment of governments
and philanthropy. We use the contribution of diseases
to the global disease burden measured in DALYs as an
incomplete and controversial proxy for the proportion of
R&D efforts which should ideally be directed toward
specific diseases. To quantify the magnitude of the im-
balance between R&D efforts and assumed R&D needs
for specific diseases  that is, the size of the R&D Gap 
we calculate the R&D expenditure in US$ per DALY for
individual diseases and disease groups. This metric has
been used in previous studies on neglect in R&D (6, 13,
22, 23). In addition, we propose the neglect factor (NF) as
a new summary measure, with the following definition:
Neglect Factor ¼
Disease burden in DALYs in % of the total global disease burdenð Þ
R&D expenditure ðin % of total global health-related R&D expenditureÞ
Table 1. The WHO classification of diseases according to their relatedness to the level of economic development and our
proposed substratification and nomenclature
Verbal definition of the WHO
Commission on Macroeconomics
and Health in 2001
Operationalization proposed by
the WHO Secretariat (18) and
Røttingen et al. (13)
Our proposed substratification
and nomenclature.
Disease type I ‘Type I diseases are incident in both rich
and poor countries, with large numbers
of vulnerable population in both’ (21).
Diseases for which the disease burden in
low- and middle-income countries (LMIC)
is not more than three times higher than in
high-income countries (HIC), measured in
DALYs (disability-adjusted life years) per
100,000 inhabitants (13, 18).
Type Ia diseases, or strongly
affluence-related diseases, with
an income relation factor,
IRFB0.33.
Type Ib diseases, or moderately
affluence-related diseases, with
0.33]IRFB0.66.
Type Ic diseases, or diseases
unrelated to the level of economic
development, with 0.66]IRFB3.
Disease type II Type II diseases ‘are incident in both rich
and poor countries, but with a
substantial proportion of the cases in
poor countries’ (21).
Diseases for which the disease burden in
LMIC is at least three but not more than
35 times higher than in HIC (13, 18).
Type II diseases, or moderately
poverty-related diseases, with
3]IRFB35 (13, 18).
Disease type III Type III diseases are diseases ‘that are
overwhelmingly or exclusively incident in
developing countries’ (21).
Diseases for which the disease burden in
LMIC is more than 35 times higher than in
HIC (13, 18).
Type II diseases, or strongly
poverty-related diseases, with
IRF]35 (13, 18).
Poverty-related and neglected diseases
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For R&D expenditure, we used data provided by G-
FINDER (Global Funding of Innovation for Neglected
Diseases) (23, 24) and Chakma et al. (25). G-FINDER
includes comprehensive R&D expenditure data on 30
diseases fulfilling three criteria: 1) the disease dispropor-
tionately affects people in developing countries; 2) there
is a need for new pharmaceutical products; and 3) there is
a market failure, that is, a commercial market insufficient
to attract industry R&D (23). Of these 30 diseases, we
exclude four diseases which are not included in GBD 2010,
and for which we therefore lack comparable disease bur-
den data (see methodological appendix, Supplementary
file 1, for details).
Development and regional distribution of the burden
of poverty-related and neglected diseases
To track the public health relevance of poverty-related and
neglected diseases (PRND) over time, and to understand
possible reasons for their neglect, we analyze the develop-
ment of the disease burden caused by PRND over the past
20 years, and the geographical distribution of the disease
burden over the 21 regions covered in GBD 2010. For all
figures based on GBD 2010 data, we calculate 95% uncer-
tainty intervals based on the 95% uncertainty intervals as
reported in GBD 2010 (please refer to the methodological
appendix, Supplementary file 1, for details).
Results
Relatedness of diseases, injuries, and risk factors to
the level of economic development
In 2010, the overall IRF for all causes was 1.4, indicating
an approximately 1.4 times higher total disease burden
per capita in LMIC compared to high-income countries
(HIC). This is a decrease from 1990, when the overall
IRF was 1.8. The relatedness of major disease groups to
the level of economic development is presented in Table 2.
Data for all 291 diseases, injuries, and cause groups in-
cluded in the GBD 2010 are presented in Supplementary
file 2. Table 3 presents the IRF for the main risk factor
clusters analyzed in GBD 2010 (data on all 67 risk factors
are provided in Supplementary file 3). In 2010, the dis-
ease burden attributable to risk factors associated with
unimproved water and sanitation, as well as child and
maternal undernutrition, was much higher in LMIC
than in HIC (IRF 107 and 34, respectively). By contrast,
the disease burden attributable to dietary risk factors,
physical inactivity, physiological risk factors, alcohol and
drug use, and tobacco smoking was 1020% higher in
HIC than in LMIC, resulting in an IRF between 0.9 and
0.8 (up from 0.7 to 0.6 in 1990).
R&D expenditure and neglect in R&D
Between 2008 and 2012, for the 26 PRND included in our
analysis of neglect, on average a total of US$3,556
million (in nominal 2012 US$) was spent on R&D
annually, based on G-FINDER data (23, 24). In the
same time period, US$265,920 million (in nominal 2012
US$) was spent in average annually on total health-
related R&D worldwide, based on figures published by
Chakma et al. (25). Thus, between 2008 and 2012, 1.34%
of total global health-related R&D expenditure was spent
on the 26 PRND included in our analysis.
Of 2,490 million DALYs lost in 2010 to all causes of
death and disability, 13.8% were caused by the 26 PRND
included in our analysis (for details on each of these,
see Fig. 2 and Table 4). From 2008 to 2012, on average
107 US$ per DALY was spent on health-related R&D
annually. For the 26 PRND in our analysis, only 10.3
US$ per DALY was spent  10 times less than the global
average for all diseases. This is summed up by the NF of
10.3 for these 26 diseases combined, showing that the
proportion of the global disease burden caused by these
diseases is roughly 10 times larger than the proportion of
total global health-related R&D expenditure spent on
them. Figures 3 and 4 show detailed results for the 26
diseases and diseases groups. Figure 5 tracks the disease
burden caused by these 26 diseases over the past 20 years,
and Fig. 6 analyzes the geographical distribution of the
disease burden caused by PRND.
Discussion
Relatedness of diseases, injuries, and risk factors to
the level of economic development
Our analysis reveals that the number of poverty-related
diseases is considerably larger than existing definitions
of PRND suggest. Of the 241 individual diseases and
injuries analyzed in the GBD 2010, approximately one
third (81) are either strongly or moderately poverty related,
causing 38% of the global disease burden in 2010, down
from 51% in 1990.
The existing Type I disease category (0]IRFB3),
encompassing all diseases not related to poverty, contains
165 diseases and injuries, responsible for 61% of the
global disease burden in 2010. This disease group in-
cludes diseases such as Dengue (IRF 2.9), which causes
three times more DALY per capita in LMIC compared
to HIC, as well as diseases such as prostate cancer (IRF
0.16) causing approximately seven times more DALYs
per capita in HIC than in LMIC. The large range of this
category, and the large number diseases included, war-
rant a substratification.
Based on our proposed substratification, 43 diseases
and injuries are either strongly affluence related (Type Ia,
IRFB0.33) or moderately affluence related (Type Ib,
0.33]IRFB0.66), causing 13.2% of the global disease
burden, a figure which has remained comparatively stable
since 1990. In addition, approximately half of all diseases
and injuries, responsible for half of the global disease
Peter von Philipsborn et al.
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Table 2. Relatedness of disease groups to the level of economic development
2010 1990
DALYs per 100,000 inhabitants
Disease
type
DALYs per 100,000 inhabitants
Disease
typeCause or cause group LMIC HIC IRF LMIC HIC IRF
All causes 38,041 (27,27952,476) 26,421 (19,91734,930) 1.4 (0.82.6) Ic (Ic-Ic) 51,463 (36,11573,296) 28,629 (22,17436,789) 1.8 (1.03.3) Ic (Ic-II)
Communicable, maternal, neonatal, and
nutritional disorders
14,604 (10,32220,676) 1,416 (1,0841,869) 10.3 (5.519.1) II (II-II) 26,602 (18,24139,060) 2,084 (1,6282,716) 12.8 (6.724.0) II (II-II)
HIV/AIDS and tuberculosis 2,214 (1,8422,581) 150 (132171) 14.7 (10.819.6) II (II-II) 1,746 (1,4442,160) 343 (305384) 5.1 (3.87.1) II (II-II)
Diarrhea, lower respiratory infections,
meningitis, and other common infectious
diseases
4,720 (3,1737,104) 695 (534921) 6.8 (3.413.3) II (II-II) 12,252 (8,02919,289) 840 (6441,139) 14.6 (7.029.9) II (II-II)
Neglected tropical diseases and malaria 1,856 (1,2002,863) 25 (1345) 74.8 (26.4224.2) III (II-III) 2,367 (1,5073,760) 38 (1969) 62.8 (21.9194.3) III (II-III)
Maternal disorders 273 (206365) 14 (824) 19.9 (8.544.9) II (II-III) 490 (385627) 16 (1223) 30.2 (16.750.7) II (II-III)
Neonatal disorders 3,394 (2,4554,644) 354 (283443) 9.6 (5.516.4) II (II-II) 6,134 (4,3508,216) 624 (493773) 9.8 (5.616.7) II (II-II)
Nutritional deficiencies 1,440 (1,0131,997) 118 (78173) 12.2 (5.925.5) II (II-II) 2,527 (1,8693,396) 148 (104209) 17.0 (8.932.5) II (II-II)
Other communicable, maternal, neonatal,
and nutritional disorders
707 (4331,122) 61 (3692) 11.6 (4.731.0) II (II-II) 1,087 (6571.612) 75 (49118) 14.5 (5.633.0) II (II-II)
Non-communicable diseases 19,079 (13,87025,683) 22,470 (16,89529,815) 0.8 (0.51.5) Ic (Ib-Ic) 19,841 (14,36027,282) 23,442 (18,08130,168) 0.8 (0.51.5) Ic (Ib-Ic)
Neoplasms 2,461 (1,7833,157) 4,392 (3,4015,596) 0.6 (0.30.9) Ib (Ia-Ic) 2,459 (1,8273,192) 4,575 (3,6365,773) 0.5 (0.30.9) Ib (Ia-Ic)
Cardiovascular and circulatory diseases 4,301 (3,6394,986) 4,290 (3,8774,973) 1.0 (0.71.3) Ic (Ic-Ic) 4,334 (3,6705,161) 5,774 (5,2596,239) 0.8 (0.61.0) Ic (Ib-Ic)
Chronic respiratory diseases 1,777 (1,3862,299) 1,387 (1,0681,795) 1.3 (0.82.2) Ic (Ic-Ic) 2,431 (1,9333,114) 1,453 (1,1481,853) 1.7 (1.02.7) Ic (Ic-Ic)
Cirrhosis of the liver 462 (347601) 394 (320465) 1.2 (0.71.9) Ic (Ic-Ic) 462 (359577) 464 (388546) 1.0 (0.71.5) Ic (Ib-Ic)
Digestive diseases except cirrhosis 491 (354700) 391 (287553) 1.3 (0.62.4) Ic (Ib-Ic) 680 (478922) 435 (325601) 1.6 (0.82.8) Ic (Ic-Ic)
Neurological disorders 1,029 (7101,443) 1,342 (9821,733) 0.8 (0.41.5) Ic (Ib-Ic) 909 (6121,294) 1,007 (7431,324) 0.9 (0.51.7) Ic (Ib-Ic)
Other mental and behavioral disorders 20 (1330) 30 (1944) 0.7 (0.31.6) Ic (Ia-Ic) 21 (1231) 26 (1638) 0.8 (0.31.9) Ic (Ia-Ic)
Diabetes, urogenital, blood, and endocrine
diseases
1,761 (1,2552,495) 1,916 (1,3802,780) 0.9 (0.51.8) Ic (Ib-Ic) 1,626 (1,0982,536) 1,577 (1,1522,211) 1.0 (0.52.2) Ic (Ib-Ic)
Musculoskeletal disorders 2,247 (1,5773,068) 3,762 (2,6395,084) 0.6 (0.31.2) Ib (Ia-Ic) 1,967 (1,3642,690) 3,447 (2,4144,664) 0.6 (0.31.1) Ib (Ia-Ic)
Other non-communicable diseases 1,930 (1,0923,180) 1,441 (7872,443) 1.3 (0.44.0) Ic (Ib-II) 2,504 (1,4014,232) 1,705 (9742,759) 1.5 (0.54.3) Ic (Ib-II)
Injuries 4,358 (3,0876,117) 2,535 (1,9373,246) 1.7 (1.03.2) Ic (Ic-II) 5,020 (3,5146,954) 3,104 (2,4663,905) 1.6 (0.92.8) Ic (Ic-Ic)
Transport injuries 1,295 (9461,773) 701 (570874) 1.8 (1.13.1) Ic (Ic-II) 1,200 (7971,705) 1,060 (8731,278) 1.1 (0.62.0) Ic (Ib-Ic)
Unintentional injuries other than transport
injuries
1,872 (1,3512,549) 1,128 (8501,482) 1.7 (0.93.0) Ic (Ic-Ic) 2,722 (1,9493,725) 1,182 (9221,517) 2.3 (1.34.0) Ic (Ic-II)
Self-harm and interpersonal violence 948 (6471,315) 690 (508865) 1.4 (0.72.6) Ic (Ic-Ic) 957 (6701,300) 848 (6631,088) 1.1 (0.62.0) Ic (Ib-Ic)
Forces of nature, war, and legal intervention 243 (142481) 17 (1026) 14.7 (5.646.2) II (II-III) 141 (98223) 14 (822) 10.2 (4.427.1) II (II-II)
Own calculations based on Global Burden of Disease Study 2010 data. DALYs: disability-adjusted life years; LMIC: low- and middle-income countries; HIC: high-income countries; IRF:
income relation factor, ratio of DALYs per 100,000 inhabitants in LMIC versus HIC; Disease Type Ia: strongly affluence-related diseases; Ib: moderately affluence related; Ic: unrelated to the
level of economic development; II: moderately poverty related; III: strongly poverty related. In brackets, the 95% uncertainty interval is given, based on GBD 2010 figures. For details, please





































































































Table 3. Relatedness of risk factors and risk factor clusters to the level of economic development
2010 1990
Risk factor or risk factor
cluster
DALYs per 100,000 inhabitants
Risk factor
type
DALYs per 100,000 inhabitants
Risk factor
typeLMIC HIC IRF LMIC HIC IRF
Unimproved water and
sanitation
362 (15708) 3 (08) 106.8 (2.05146.9) III (Ic-III) 1,191 (612,175) 9 (019) 137.9 (3.36081.3) III (II-III)
Unimproved water source 133 (8281) 2 (03) 85.5 (2.43097.8) III (Ic-III) 483 (33972) 4 (09) 121.5 (3.84005.0) III (II-III)
Unimproved sanitation 255 (6516) 2 (04) 137.4 (1.511347.7) III (Ic-III) 824 (251,559) 5 (011) 168.9 (2.313871.5) III (Ic-III)
Air pollution 2,649 (2,2193,131) 590 (497699) 4.5 (3.26.3) II (II-II) 4,776 (3,9615,601) 1,179 (1,0111,341) 4.0 (3.05.5) II (Ic-II)
Ambient particulate matter
pollution
1,203 (1,0321,387) 577 (491668) 2.1 (1.52.8) Ic (Ic-Ic) 1,643 (1,3661,946) 1,112 (9731,248) 1.5 (1.12.0) Ic (Ic-Ic)
Household air pollution
from solid fuels
1,848 (1,3972,358) 7 (027) 279.7 (52.174103.8) III (III-III) 3,888 (3,0384,705) 79 (26126) 49.1 (24.1183.5) III (II-III)
Ambient ozone pollution 39 (1368) 17 (632) 2.3 (0.412.1) Ic (Ib-II) 52 (1795) 28 (1047) 1.9 (0.49.8) Ic (Ib-II)
Other environmental risks 240 (175323) 197 (135276) 1.2 (0.62.4) Ic (Ib-Ic) 107 (80139) 77 (6197) 1.4 (0.82.3) Ic (Ic-Ic)
Residential radon 26 (372) 58 (8131) 0.5 (0.09.5) Ib (Ia-II) Not assessed for 1990 because of absence of exposure data
Lead exposure 214 (158280) 139 (110174) 1.5 (0.92.5) Ic (Ic-Ic) 107 (80139) 77 (6197) 1.4 (0.82.3) Ic (Ic-Ic)
Child and maternal
undernutrition
2,827 (2,2833,477) 83 (59118) 33.9 (19.358.8) II (II-III) 7,748 (6,3289,497) 134 (99176) 58.0 (35.996.0) III (III-III)
Suboptimal breastfeeding 812 (4741,213) 5 (38) 160.8 (58.4475.8) III (III-III) 2,518 (1,4983,630) 21 (1132) 122.6 (47.6330.3) III (III-III)
Childhood underweight 1,322 (1,0401,674) 3 (25) 421.3 (217.2792.6) III (III-III) 4,520 (3,6905,630) 12 (817) 362.5 (215.3682.5) III (III-III)
Iron deficiency 813 (5641,147) 70 (47103) 11.6 (5.524.4) II (II-II) 1,167 (8361,620) 91 (66128) 12.8 (6.524.5) II (II-II)
Vitamin A deficiency 184 (91310) 1 (03) 149.6 (36.2716.9) III (III-III) 692 (3211,287) 3 (16) 240.8 (54.71268.6) III (III-III)
Zinc deficiency 156 (37301) 4 (28) 35.3 (4.5148.3) III (II-III) 556 (1131,073) 8 (415) 69.2 (7.7287.7) III (II-III)
Tobacco smoking. including
secondhand smoke
2,208 (1,8532,540) 2,729 (2,3763,072) 0.8 (0.61.1) Ic (Ib-Ic) 2,722 (2,3063,179) 3,696 (3,3564,070) 0.7 (0.60.9) Ic (Ib-Ic)
Tobacco smoking 1,887 (1,5462,204) 2,614 (2,2522,957) 0.7 (0.51.0) Ic (Ib-Ic) 1,899 (1,5722,288) 3,463 (3,1123,852) 0.5 (0.40.7) Ib (Ib-Ic)
Secondhand smoke 321 (233417) 115 (76161) 2.8 (1.45.5) Ic (Ic-II) 823 (5911,068) 233 (165300) 3.5 (2.06.5) II (Ic-II)
Alcohol and drug use 2,201 (1,9012,547) 2,718 (2,4482,997) 0.8 (0.61.0) Ic (Ib-Ic) 2,039 (1,7652,371) 3,376 (3,0903,688) 0.6 (0.50.8) Ib (Ib-Ic)
Alcohol use 1,890 (1,6302,199) 2,208 (2,0152,422) 0.9 (0.71.1) Ic (Ic-Ic) 1,793 (1,5552,094) 2,919 (2,6863,179) 0.6 (0.50.8) Ib (Ib-Ic)
Drug use 316 (228431) 527 (404674) 0.6 (0.31.1) Ib (Ib-Ic) 250 (178353) 480 (370617) 0.5 (0.31.0) Ib (Ia-Ic)
Physiological risk factors 4,149 (3,7664,519) 4,764 (4,3735,215) 0.9 (0.71.0) Ic (Ic-Ic) 3,608 (3,3143,937) 5,793 (5,4266,145) 0.6 (0.50.7) Ib (Ib-Ic)
High fasting plasma
glucose
1,302 (1,0301,592) 1,269 (1,0341,531) 1.0 (0.71.5) Ic (Ic-Ic) 1,029 (8281,244) 1,284 (1,0571,526) 0.8 (0.51.2) Ic (Ib-Ic)
High total cholesterol 553 (328792) 843 (6511,059) 0.7 (0.31.2) Ib (Ia-Ic) 590 (441747) 1,551 (1,3101,809) 0.4 (0.20.6) Ib (Ia-Ib)
High blood pressure 2,571 (2,2132,915) 2,290 (1,9222,654) 1.1 (0.81.5) Ic (Ic-Ic) 2,410 (2,1202,706) 3,570 (3,2353,897) 0.7 (0.50.8) Ic (Ib-Ic)
High body mass index 1,198 (9311,485) 2,317 (1,9692,692) 0.5 (0.30.8) Ib (Ib-Ic) 756 (565964) 2,089 (1,7332,449) 0.4 (0.20.6) Ib (Ia-Ib)






























































































Table 3 (Continued )
2010 1990
Risk factor or risk factor
cluster
DALYs per 100,000 inhabitants
Risk factor
type
DALYs per 100,000 inhabitants
Risk factor
typeLMIC HIC IRF LMIC HIC IRF
Dietary risk factors and
physical inactivity
3,669 (3,3473,977) 3,924 (3,6394,248) 0.9 (0.81.1) Ic (Ic-Ic) 3,132 (2,8403,435) 4,550 (4,1944,859) 0.7 (0.60.8) Ic (Ib-Ic)
Diet low in fruits 1,582 (1,2101,914) 1,141 (8621,415) 1.4 (0.92.2) Ic (Ic-Ic) 1,521 (1,1681,848) 1,575 (1,1681,946) 1.0 (0.61.6) Ic (Ib-Ic)
Diet low in vegetables 568 (357778) 530 (362693) 1.1 (0.52.2) Ic (Ib-Ic) 564 (350778) 776 (5261,014) 0.7 (0.31.5) Ic (Ib-Ic)
Diet low in whole grains 621 (481755) 440 (336539) 1.4 (0.92.2) Ic (Ic-Ic) 559 (432685) 559 (425688) 1.0 (0.61.6) Ic (Ib-Ic)
Diet low in nuts and seeds 730 (468956) 846 (5381,101) 0.9 (0.41.8) Ic (Ib-Ic) 666 (429867) 1,289 (8331,656) 0.5 (0.31.0) Ib (Ia-Ic)
Diet low in milk 25 (743) 62 (18105) 0.4 (0.12.4) Ib (Ia-Ic) 23 (738) 60 (18101) 0.4 (0.12.2) Ib (Ia-Ic)
Diet high in red meat 22 (1038) 55 (2686) 0.4 (0.11.5) Ib (Ia-Ic) 17 (728) 53 (2583) 0.3 (0.11.1) Ia (Ia-Ic)
Diet high in processed
meat
271 (82483) 499 (182804) 0.5 (0.12.6) Ib (Ia-Ic) 261 (73465) 669 (2011,123) 0.4 (0.12.3) Ib (Ia-Ic)
Diet high in sugar-
sweetened beverages
126 (72199) 119 (73182) 1.1 (0.42.7) Ic (Ib-Ic) 101 (52168) 114 (68179) 0.9 (0.32.5) Ic (Ia-Ic)
Diet low in fiber 228 (95371) 306 (149468) 0.7 (0.22.5) Ic (Ia-Ic) 215 (92347) 444 (204689) 0.5 (0.11.7) Ib (Ia-Ic)
Diet low in calcium 33 (2343) 68 (4494) 0.5 (0.31.0) Ib (Ia-Ic) 29 (2138) 62 (4185) 0.5 (0.20.9) Ib (Ia-Ic)
Diet low in seafood
omega-3 fatty acids




163 (75252) 214 (103324) 0.8 (0.22.5) Ic (Ia-Ic) 159 (75244) 334 (160512) 0.5 (0.11.5) Ib (Ia-Ic)
Diet high in trans fatty
acids
154 (108202) 254 (184330) 0.6 (0.31.1) Ib (Ia-Ic) 107 (74142) 383 (273492) 0.3 (0.20.5) Ia (Ia-Ib)
Diet high in sodium 907 (5831,212) 806 (5121,080) 1.1 (0.52.4) Ic (Ib-Ic) 844 (5421,125) 1,046 (6651,403) 0.8 (0.41.7) Ic (Ib-Ic)
Physical inactivity and low
physical activity
958 (7931,134) 1,311 (1,1261,510) 0.7 (0.51.0) Ic (Ib-Ic) Not assessed for 1990 because of absence of exposure data
Occupational risk factors 984 (7401,272) 491 (382623) 2.0 (1.23.3) Ic (Ic-II) 1,128 (8621,420) 686 (565831) 1.6 (1.02.5) Ic (Ic-Ic)
Occupational carcinogens 35 (2052) 62 (4483) 0.6 (0.21.2) Ib (Ia-Ic) 26 (1641) 68 (5193) 0.4 (0.20.8) Ib (Ia-Ic)
Occupational asthmagens 31 (2050) 21 (1431) 1.5 (0.73.7) Ic (Ib-II) 43 (2674) 26 (1838) 1.6 (0.74.1) Ic (Ic-II)
Occupational particulate
matter, gases, and fumes
150 (70237) 38 (1466) 4.0 (1.116.5) II (Ic-II) 210 (98327) 41 (1670) 5.1 (1.420.4) II (Ic-II)
Occupational noise 56 (3390) 19 (1131) 3.0 (1.18.4) Ic (Ic-II) 60 (3597) 26 (1544) 2.3 (0.86.4) Ic (Ic-II)
Occupational risk factors
for injuries
382 (250574) 112 (93140) 3.4 (1.86.2) II (Ic-II) 434 (285629) 260 (220302) 1.7 (0.92.9) Ic (Ic-Ic)





































































































burden (49% in 2010, up from 34% in 1990), are unrelated
to the level of economic development (disease Type Ic,
0.66]IRFB3). Most non-communicable diseases, in-
cluding many cardiovascular and neuropsychiatric dis-
orders, are found in this category.
This highlights general patterns in the global epide-
miological transition. The IRF figures clearly illustrate the
double burden of communicable and non-communicable
diseases faced by LMIC, showing that while communic-
able diseases (IRF 10.3) are strongly concentrated in
LMIC, non-communicable diseases (IRF 0.8) are causing
almost as many DALYs per capita in LMIC as in HIC.
Neoplasms (IRF 0.6) are the only main disease group
causing a considerably smaller number of DALYs per
capita in LMIC than in HIC, while still qualifying as only
moderately affluence related.
Remarkably, this double burden has decreased since
1990, as the burden of non-communicable diseases has
decreased simultaneously in LMIC and in HIC (IRF 0.8
constant since 1990), while the burden of communicable
diseases has decreased more rapidly in LMIC than in
HIC (IRF 10.3 in 2010, down from 12.8 in 1990). The
burden of injuries has decreased both in LMIC and in
HIC, but slightly faster in HIC (IRF 1.7 in 2010, up
from 1.6 in 1990). Thus, while it is true that LMIC face
actually a triple burden of communicable diseases, non-
communicable diseases, and injuries, this phenomenon
has grown less acute since 1990.
Our analysis of the relatedness of risk factors to the
level of economic development reveals similar patterns
for the year 2010, showing a double burden of risk factors
in LMIC: among the 10 major risk factor clusters analy-
zed in the GBD 2010, there are two which are strongly
poverty related (unimproved water and sanitation, and
child and maternal undernutrition), one which is moder-
ately poverty related (air pollution) and seven which are
unrelated to the level of economic development, causing
a similar amount of DALYs in HIC and in LMIC. Global
disparities in risk factor exposure patterns were higher
than those in disease burden patterns in 1990, and have
converged more consistently since then.
Among the 81 strongly or moderately poverty-related
conditions, a considerable number are infectious diseases
which can be treated or prevented with existing pharma-
ceuticals. For others, for example, accidents, intentional
injuries, and certain maternal and neonatal conditions
such as birth trauma and abortion, pharmaceuticals are
of limited usefulness. This shows that the lack of phar-
maceutical R&D on neglected diseases is only one among
many health challenges specific to LMIC. Moreover,
this highlights that for a considerable number of poverty-
related causes of death and disability, policy action
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Health-related R&D expenditure and neglect in R&D
The 26 PRND included in our analysis are responsible
for 14% of the global disease burden, but receive only
1.3% of global health-related R&D expenditure. In 1990,
the Global Commission on Health Research identified a
‘10/90 Gap’, in global health R&D, based on the assump-
tion that in 1990, less than 5% of global health R&D was
spent on diseases specific to developing countries, while
93% of the world’s preventable mortality occurs in this
group of countries (26). Following this commonly used
terminology and based on the results of our analysis, we
can thus identify a ‘1.3/14 Gap’ in global health-related
R&D. However, variation within this group of PRND is
large, as shown by the wide range of the NF (median: 19;
range: 544 (0.06544); interquartile range (IQR): 47 (6
52)) and the Dollar per DALY metric (median: 28; range:
9,570 (19,571); IQR: 83 (1094)). Despite this variation,
our results clearly show that a large shortfall in R&D
funding for PRND persists.
The relative contribution of these 26 PRND to the
global disease burden has remained relatively stable over
the past 20 years (13.8% in 2010 down from 14.4% in
1990), with shifting shares of individual PRND (see Fig. 5).
By contrast, the role of the larger set of strongly and
moderately poverty-related diseases identified in the first
part of our analysis has decreased strongly from 51%
of the global disease burden in 1990 to 38% in 2010. This
shows that the 26 PRND in our analysis are, unlike the
larger set of poverty-related diseases, not only poverty
related but also neglected. While poverty-related diseases
more generally are receding, the R&D gap for PRND,
and their contribution to the global disease burden, over
the past 20 years, has not grown significantly smaller
in the course of the global epidemiological transition. It is
therefore unlikely to disappear without increased action
by public and private actors. For this action to be effective,
however, better data on PRND is needed, suggesting a
rationale for a WHO Global Health R&D Observatory
(13, 17). Moreover, recent national and international policy
initiatives such as the WHO R&D Demonstration Projects
should be considered in this context (27).
Limitations
In our categorization of diseases into diseases Types I, II,
and III, we followed the approach used by the WHO
Secreteriat and Røttingen et al., although noting limita-
tions outlined by them (13, 18). The choice of the cut-off
values between the different disease categories is arbitrary
to a certain degree, which is aggravated by the fact that
the relative size of the disease categories is highly sensitive
to the cut-off value. In addition, the DALY figures used
are not age weighted.
Moreover, it should be noted that the IRF metric used
in our analysis was originally developed for use with
data from the GBD 2004 study, which uses a different
methodology compared to the one used by GBD 2010.
Therefore, our results are not directly comparable to the
results reported in the original WHO background docu-
ment (17) and Røttingen et al. (13). (For details please






























Bact. Pneumonia & Meningitis
Salmonella infections







Global disease burden, as % of the total global disease
burden in DALYs, 2010
R&D expenditure, as % of total worldwide health-
related R&D expenditure, 2008-2012 annual average
Global disease burden and R&D expenditure compared
Fig. 2. Disease burden in DALYs (as % of total global disease burden, 2010) and R&D Expenditure (as % of total global health
R&D Expenditure, annual average for 20082010) for 11 diseases and disease groups as defined by G-FINDER. Source: Own
calculation based on Global Burden of Disease Study 2010 and G-FINDER data and data published by Chakma et al. DALYs:
disability adjusted life years; R&D: research and development.
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DALYs per 100,000 inhabitants
Disease
typeCause or cause group Neglect factor Dollar per DALY LMIC HIC IRF
All causes 100 (100100) 100.00 1 (11) 107 (83139) 38041.42 (27279.0152476.16) 26421.32 (19916.7334930.07) 1.44 (.782.63) Ic (Ic-Ic)
All G-FINDER diseases 13.82 (10.3518.14) 1.34 10.3 (7.713.6) 10 (813) 5808.1 (4,2437,765) 468.9 (385573) 12.4 (720) II (II-II)
HIV AIDS 3.27 (2.813.80) 0.48 6.9 (5.98.0) 16 (1417) 1376.3 (1,1881,571) 108.9 (98121) 12.6 (1016) II (II-II)
Malaria 3.32 (2.404.68) 0.24 13.7 (9.919.3) 8 (610) 1414.6 (9612,050) 0.1 (01) 11465.2 (1,2681,303,421) III (III-III)
Tuberculosis 1.98 (1.522.39) 0.23 8.8 (6.710.6) 12 (1115) 837.9 (6541,010) 41.4 (3451) 20.3 (1330) II (II-II)
Diarrheal diseases 1.82 (1.352.37) 0.07 27.1 (20.035.2) 4 (35) 769.0 (5331,068) 47.3 (3170) 16.3 (835) II (II-II)
Rotavirus 0.75 (.55.97) 0.02 34.6 (25.344.8) 3 (34) 315.8 (221428) 18.7 (1227) 16.9 (835) II (II-II)
Enterotoxigenic E. coli (ETEC) 0.28 (.21.35) 0.00 104.8 (80.7133.6) 1 (11) 114.9 (83155) 17.5 (1126) 6.6 (314) II (II-II)
Cholera 0.18 (.13.25) 0.01 14.9 (10.520.5) 7 (610) 76.3 (46119) 0.0 (00) 3156.8 (70813,273) III (III-III)
Shigella 0.28 (.22.36) 0.01 30.9 (23.539.4) 3 (34) 119.3 (87162) 7.5 (511) 15.9 (833) II (II-II)
Cryptosporidium 0.34 (.25.44) 0.00 82.5 (60.2108.7) 1 (12) 142.6 (95205) 3.6 (26) 39.8 (15107) III (II-III)
Dengue 0.03 (.01.06) 0.08 0.4 (.2.7) 266 (155637) 13.3 (529) 4.7 (28) 2.9 (114) Ic (Ib-II)
Kinetoplastids 0.18 (.10.33) 0.06 2.8 (1.55.3) 38 (2266) 74.7 (38140) 5.4 (311) 13.9 (355) II (II-III)
Chagas disease 0.02 (.01.04) 0.01 2.3 (1.14.7) 46 (2493) 8.5 (418) 4.9 (210) 1.7 (08) Ic (Ib-II)
Leishmaniasis 0.13 (.08.21) 0.02 5.5 (3.48.6) 19 (1330) 56.7 (3392) 0.5 (01) 117.7 (45290) III (III-III)
Sleeping sickness 0.02 (.00.08) 0.02 1.4 (.24.6) 78 (25574) 9.6 (130)  a III (III-III)
Helminths (worms & flukes) 0.49 (.27.88) 0.03 14.9 (8.026.7) 7 (413) 209.6 (114381) 1.6 (13) 130.4 (37479) III (III-III)
Roundworm (ascariasis) 0.05 (.03.10) 0.00 63.3 (32.4119.9) 2 (13) 22.4 (1240) 0.4 (01) 50.6 (12205) III (II-III)
Hookworm (Ancylostomiasis &
Nectoriasis)
0.13 (.06.24) 0.00 34.3 (17.064.5) 3 (26) 55.1 (27102) 0.9 (02) 59.5 (16212) III (II-III)
Whipworm (trichuriasis) 0.03 (.01.05) 0.00 60.3 (31.2106.3) 2 (13) 10.9 (618) 0.0 (00) 1110.4 (3233,864) III (III-III)
Lymphatic filariasis (elephantiasis) 0.11 (.07.17) 0.01 19.4 (11.929.7) 5 (48) 47.5 (3169)  a III (III-III)
Onchocerciasis (river blindness) 0.02 (.01.03) 0.00 4.8 (3.36.8) 22 (1730) 8.5 (611)  a III (III-III)
Schistosomiasis (bilharziasis) 0.13 (.06.27) 0.01 13.0 (6.326.1) 8 (416) 56.6 (27127)  a III (III-III)
Tapeworm (cysticercosis/taeniasis) 0.02 (.01.03) 0.00 19.1 (13.526.6) 6 (47) 8.6 (613) 0.2 (00) 37.7 (13116) III (II-III)
Bacterial pneumonia & meningitis 1.61 (1.331.91) 0.04 41.3 (34.148.9) 3 (23) 654.9 (528805) 178.6 (151209) 3.7 (35) II (Ic-II)
Streptococcus pneumoniae 1.40 (1.161.66) 0.03 51.1 (42.460.4) 2 (22) 567.9 (458697) 171.0 (145200) 3.3 (25) II (Ic-II)
Neisseria meningitidis 0.21 (.17.25) 0.01 35.2 (28.342.6) 3 (34) 87.0 (70107) 7.6 (69) 11.4 (817) II (II-II)
Salmonella infections 0.69 (.211.23) 0.02 35.9 (10.964.5) 3 (29) 289.7 (83513) 14.7 (823) 19.6 (465) II (II-III)
Non-typhoidal Salmonella enterica
(NTS)
0.19 (.14.25) 0.01 29.7 (22.138.6) 4 (35) 81.1 (55117) 10.5 (715) 7.7 (416) II (II-II)
Typhoid and paratyphoid fever
(S. typhi, S. paratyphi A)
0.49 (.06.98) 0.01 56.4 (7.4112.6) 2 (114) 208.7 (28395) 4.2 (18) 49.4 (3725) III (II-III)
Leprosy 0.00 (.00.00) 0.00 0.1 (.0.1) 1,914 (1,0264,361) 0.1 (00) 0.0 (00) 65.8 (81,110) III (II-III)
Rheumatic fever 0.41 (.34.48) 0.00 544.2 (458.6642.8) 0 (00) 162.1 (136190) 66.2 (5876) 2.4 (23) Ic (Ic-II)
Trachoma 0.01 (.01.02) 0.00 5.8 (4.08.0) 18 (1425) 5.7 (48)  a III (III-III)
Own calculations based on Global Burden of Disease Study 2010 and G-FINDER data and data published by Chakma et al. (25). DALYs: disability-adjusted life years; LMIC: low- and
middle-income countries; HIC: high-income countries; IRF: income relation factor, ratio of DALYs per 100,000 inhabitants in LMIC versus HIC; Disease Type Ia: strongly affluence-related
































































































note that the IRF captures only health disparities across
countries, and not those within countries.
Our analysis of neglect in R&D based on R&D expen-
diture and disease burden also has a number of limita-
tions. Even for diseases not related to poverty, additional
R&D needs specific to resource-poor settings may exist,
which may not be addressed by commercially driven
R&D geared toward high-income settings. This ‘intra-
disease R&D gap’ is not captured by our analysis. More-
over, the disease burden measured in DALYs is a very
crude measure for R&D needs. The equitable and effi-
cient level of R&D on a specific disease might depend,
among other things, on: 1) the relative epidemiological
and public health relevance of the disease; 2) the suit-
ability and viability of existing medical and non-medical
prevention and treatment options, and thus the medical
need for new or improved pharmaceuticals; 3) the scien-
tific and technical prospects of successfully developing
new or improved pharmaceuticals for the disease in ques-
tion; 4) the potential contribution these new remedies
could make in fighting the disease under the given political,
economic, social, and socioeconomic conditions. All four
factors depend at least partly on facts which are unknown,
uncertain, controversial, and/or difficult to assess in a sys-
tematic, comprehensive, and scientifically rigorous way,
while only the first point is addressed by the DALY mea-
sure which we have used. This is a considerable limita-
tion. Particularly important in light of the concentration
of PRND in the poorest countries (see Fig. 6) is that
























































Bacterial Pneumonia & Meningitis
Streptococcus pneumoniae




Enterotoxigenic E. coli (ETEC)
Rheumatic Fever
US$ R&D expenditure (2008-2012 annual average) per DALY (2010)
$266 (95CI: 155-637)
$1914 (95CI: 1026-4361)
Dollar/DALY (US Dollar R&D Expenditure per disability-adjusted life year, 2008-2012 annual average)
(95CI: 25-574)
All PRND (G-FINDER definition)
All causes of death and disability
Fig. 3. R&D expenditure (20082012 annual average, in 2012 nominal US$) per DALY (2010). Source: Own calculations based
on Global Burden of Disease Study 2010, G-FINDER data and data published by Chakma et al. DALYs: disability adjusted life
years; R&D: research and development.
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will severely limit the benefits of any new drugs for
PRND. This implies that measures to address the R&D
gap will only realize their full potential if complemented
with a strengthening of national health systems.
Moreover, considerable uncertainties are attached to
the data we have used in our analysis, namely the disease
burden data and the R&D expenditure data for total
global biomedical R&D and for specific neglected dis-
eases, which we have taken from different sources (19, 20,
23, 24). For figures on specific neglected diseases, we used
the G-FINDER, which uses very strict inclusion criteria
and only considers funding data verified both by donors
and receiving R&D organizations (23). This implies that
G-FINDER data on R&D funding are lower-bound
estimates. By contrast, for total world-wide biomedical
R&D expenditure, we used figures provided by Chakma
et al., who use publicly reported as well as interpolated
data (25). Moreover, uncertainties are attached to the mea-
sures used by Chakma et al. for inflation and purchasing
power adjustments, as pointed out by Young et al. (28).
For our own calculations, we used the National Insti-
tutes of Health Biomedical R&D Price Index to adjust for
inflation, which is an equally imperfect measure (28).
Uncertainties are also attached to the disease burden data
we use (19, 20). These may be particularly large for the
neglected tropical diseases we have analyzed (29, 30).
Moreover, varying definitions of PRND exist (3, 13, 23,
3133), of which we have chosen only one.
Results of similar studies
The results of our study are consistent with earlier studies
on disparities in disease burden patterns and global health
R&D. Røttingen et al. showed that in 2010 roughly 1% of
global health-related R&D investment was spent on
PRND (13). Pedrique et al. show that only 1% of clinical
trials registered between 1999 and 2011 are devoted to
PRND and between 2000 and 2011 only 1.2% of new che-
mical entities were developed for PRND that accounted
for 11% of global disease burden (3, 7). Hotez et al. and
Viergever found large variations between selected PRND
when estimating neglect in R&D using the Dollar/DALY
metric (6, 22). Evans et al. analyze the number of articles, sys-
tematic reviews, and clinical trials indexed in MEDLINE
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Rheumatic Fever
Neglect Factor (disease burden as % of total / R&D expenditure as % of total)
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Fig. 4. The neglect factor for 26 poverty-related diseases. The neglect factor is the ratio of disease burden in DALYs
(as a percentage of the total global disease burden, 2010) versus R&D expenditure (as a percentage of total global health-related
R&D expenditure, 20082012 average). Source: Own calculations based on Global Burden of Disease Study 2010, G-FINDER
data and data published by Chakma et al. DALYs: disability adjusted life years; R&D: research and development.
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global DALYs for each condition had a small, significant
negative relationship with the production of each type
of MEDLINE articles for that condition (3). Trouiller
et al. had reported earlier that of 1,393 new chemical
entities marketed between 1975 and 1999, only 16 or
roughly 1% was for tropical diseases and tuberculosis,
while these diseases were responsible for 11.4% of the
global disease burden (11). However, Cohen et al. found
for the same time period and the same set of diseases
a considerably higher number of new chemical entities
(32 or roughly 2%) (34). Viergever, Karam, and Terry find
that for every million DALYs caused by communicable,
maternal, perinatal, and nutritional conditions, by non-
communicable diseases, or by injuries, the WHO’s Inter-
national Clinical Trials Registry Platform (ICTRP)
database contains an estimated 7.4, 52.4, and 6.0 trials,
respectively (35). Despite differences in methodology,
scope, and time frame, these findings are consistent with
the results of our analysis.
Conclusions
The disease burden caused by individual diseases, disease
groups, and risk factors varies strongly with the level
of economic development, as demonstrated by the wide
range of the IRF. Communicable, neonatal, maternal,
and nutritional disorders cause a 10 times larger disease
burden per capita in LMIC than in HIC (IRF 10.3).
Non-communicable diseases cause only a slightly smaller
disease burden per capita in LMIC than in HIC (IRF 0.8),
demonstrating the double burden of communicable and
non-communicable diseases in LMIC. The 26 poverty-
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Fig. 5. The overall contribution of PRND to the global burden of disease has remained comparatively stable over the past
20 years, with marked changes in the relative weight of individual disease. Source: Own calculations based on Global Burden of
Disease Study 2010. Disease groups are defined as in G-FINGER, excluding four diseases for which no disease burden data were
available.
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R&D are responsible for 13.8% of the global disease burden,
but receive only 1.34% of global health-related R&D
expenditure. These findings reveal a considerable shortfall
in R&D funding for PRND. The degree of neglect, however,
as captured by the Dollar per DALY metric and the NF,
varies considerably among the different PRND.
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